Quantitative Evaluation of Multiple Treatment Regimens for Treatment-Resistant Depression [0.03%]
难治性抑郁治疗方案的量化评估研究
Yulin Feng,Yinghua Lv,Juan Yang et al.
Yulin Feng et al.
Objective: This study aims to quantitatively evaluate the efficacy and safety of various treatment regimens for treatment-resistant depression (TRD) across oral, intravenous, and intranasal routes to inform clinical guide...
The Development of Opioid Vaccines as A Novel Strategy for the Treatment of Opioid Use Disorder and Overdose Prevention [0.03%]
阿片类疫苗在治疗 opioid 使用障碍和预防过量中的新型策略研究与发展
Mustafa Tuncturk,Shikha Kushwaha,Robin M Heider et al.
Mustafa Tuncturk et al.
Opioid use disorder (OUD) affects over 40 million people worldwide, creating significant social and economic burdens. Medication for opioid use disorder (MOUD) is often considered the primary treatment approach for OUD. MOUD, including meth...
Neurofilament light chain level is associated with lifetime suicidal behaviors [0.03%]
神经丝轻链水平与终生自杀行为有关
Ying-Chih Cheng,Yu-Li Liu,Wen-Yin Chen et al.
Ying-Chih Cheng et al.
Background: Suicide is among the severe outcomes of mental illness and has been reported to be associated with neurodegeneration and cognitive impairment. The blood neurofilament light chain (NfL) level is a biomarker of ...
Investigation of the Mesencephalic Astrocyte Derived Neurotrophic Factor-Endoplasmic Reticulum Stress Pathway in Mood Disorders [0.03%]
情绪障碍中神經调节肽-内质网应力通路的研究进展
Mohammad Ali,Bianca Wollenhaupt-Aguiar,Yifan Wang et al.
Mohammad Ali et al.
Background: Bipolar disorder (BD) has been associated with impaired cellular resilience. Recent studies have shown abnormalities in the unfolded protein response (UPR) in BD. The UPR is the cellular response to endoplasmi...
The role of pallidal substance P and neurokinin receptors in the consolidation of spatial memory of rats [0.03%]
壳内物质P及神经激肽受体在大鼠空间记忆巩固中的作用研究
Erika Kertes,László Péczely,Tamás Ollmann et al.
Erika Kertes et al.
Background: The tachykinin substance P (SP) facilitates learning and memory processes after its central administration. Activation of its different receptive sites, neurokinin-1 receptors (NK1Rs), as well as NK2Rs and NK3...
Pharmacokinetics and Pharmacodynamics of an Innovative Psychedelic N,N-Dimethyltryptamine/Harmine Formulation in Healthy Participants: A Randomized Controlled Trial [0.03%]
健康受试者中一种创新的 psychedelics N,N-二甲基色胺/ harmine 物质药代动力学及药效学：一项随机对照试验
Michael J Mueller,Helena D Aicher,Dario A Dornbierer et al.
Michael J Mueller et al.
Background: Recent interest in the clinical use of psychedelics has highlighted plant-derived medicines like ayahuasca showing rapid-acting and sustainable therapeutic effects in various psychiatric conditions. This tradi...
Therapeutic Potential of DAAO Inhibitors for Cognitive Impairment Associated with Schizophrenia: Learnings from Luvadaxistat [0.03%]
DAAO抑制剂在治疗与精神分裂症相关的认知障碍方面的潜在疗效：来自Luvadaxistat的启示
Ryan T Terry-Lorenzo,Reuben H Fan,Ni A Khin et al.
Ryan T Terry-Lorenzo et al.
Hypofunction of the N-methyl-D-aspartate receptor (NMDAR) has been proposed to underlie the pathophysiology of schizophrenia, suggesting that promoting NMDAR activity may alleviate the negative or cognitive symptoms associated with schizoph...
Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: A randomized, double-blind, placebo-controlled trial [0.03%]
吡拉西坦对稳定期精神分裂症阴性症状的辅助治疗：随机、双盲、安慰剂对照试验
Ahmad Shamabadi,Elham-Sadat Rafiei-Tabatabaei,Kimia Kazemzadeh et al.
Ahmad Shamabadi et al.
Background: Negative symptoms of schizophrenia represent an unmet therapeutic need for many patients on whom pentoxifylline may be effective in terms of its dopaminergic, anti-inflammatory, and cerebral blood flow-increas...
Disrupting heroin-associated memory reconsolidation through actin polymerization inhibition in the nucleus accumbens core [0.03%]
通过海马ACTIN聚合抑制破坏与海洛因相关的记忆再巩固
Haiting Zhao,Haoyu Li,Li Meng et al.
Haiting Zhao et al.
Background: Understanding drug addiction as a disorder of maladaptive learning, where drug-associated or environmental cues trigger drug cravings and seeking, is crucial for developing effective treatments. Actin polymeri...
Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial [0.03%]
新型抗精神病药物Evenamide治疗难治性精神分裂症阴性症状的疗效：一项随机、开放标签的II期临床研究最终结果
Ravi Anand,Alessio Turolla,Giovanni Chinellato et al.
Ravi Anand et al.
The results from a pilot, 1-year, randomized, open-label, add-on treatment study in treatment-resistant schizophrenia (TRS) with evenamide, a glutamate modulator, were not associated with any safety abnormalities at all doses (7.5-30 mg bid...